Pleiotropic Benefits of Statins in Cardiovascular Diseases
- 22 July 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 72 (09) , 477-486
Abstract
In 1976, Japanese microbiologist Akira Endo discovered the first statin as a product of the fungus Penicillium citrinum that inhibited the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Their primary mode of action is to lower the blood cholesterol by decreasing hepatic cholesterol production, which upregulates hepatic low-density lipoprotein (LDL) receptors and increases LDL-cholesterol clearance. In addition to cholesterol lowering, statins inhibit other downstream products of the mevalonate pathway, causing the so-called pleiotropic effects. As a result of their pleiotropic effects statins modulate virtually all known processes of atherosclerosis and have beneficial effects outside the cardiovascular system Statins inhibit the post-translational prenylation of small GTP-binding proteins such as Rho, Rac, as well as their downstream effectors such as Rho kinase and nicotinamide adenine dinucleotide phosphate oxidases since they suppress the synthesis of isoprenoid intermediates in the cholesterol biosynthetic pathway altering the expression of endothelial nitric oxide synthase, the stability of atherosclerotic plaques, production of proinflammatory cytokines, reactive oxygen species, platelet reactivity, development of cardiac hypertrophy and fibrosis in cell culture and animal experiments. Inhibition of Rho and Rho-associated coiled-coil containing protein kinase (ROCK), has emerged as the principle mechanisms underlying the pleiotropic effects of statins. However, the relative contributions of statin pleiotropy to clinical outcomes are debatable and difficult to measure because the amount of isoprenoid inhibition by statins corresponds to some extent with the amount of LDL-cholesterol decrease. This article examines some of the existing molecular explanations underlying statin pleiotropy and discusses if they have clinical relevance in cardiovascular diseases.Keywords
This publication has 73 references indexed in Scilit:
- High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trialEuropean Heart Journal, 2011
- Therapeutic Levels of the Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling via Phospholipase D2Molecular and Cellular Biology, 2011
- Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndromeAtherosclerosis, 2010
- Novel aspects of the roles of Rac1 GTPase in the cardiovascular systemCurrent Opinion in Pharmacology, 2010
- A Randomized Trial of Rosuvastatin in the Prevention of Venous ThromboembolismNew England Journal of Medicine, 2009
- Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic EventThe American Journal of Cardiology, 2009
- Evidence for Statin Pleiotropy in HumansCirculation, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Rho-kinase-dependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischemia–reperfusion-induced endothelial cell apoptosisApoptosis, 2007
- Requirement of Rac1 in the development of cardiac hypertrophyProceedings of the National Academy of Sciences, 2006